RAD50 and cancer: Mutations in APC, K-Ras, B-Raf, PIK3CA, TP53, ATM, SMAD4, RAD50, POLE, and PTEN are usually considered to be relevant CRC biomarkers [29,30,31,32] as cancer therapy target structures in precision medicine approaches [33].